Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease
Open Access
- 12 January 2004
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 164 (1) , 40-44
- https://doi.org/10.1001/archinte.164.1.40
Abstract
In randomized trials of secondary prevention and their meta-analyses, the 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (or statins)1-4 and aspirin5-12 have been demonstrated to reduce risks of cardiovascular disease (CVD). Indeed, regulatory authorities worldwide, including the US Food and Drug Administration, have approved the use of pravastatin sodium,13 one of the most widely tested statins, and aspirin14 in the secondary prevention of CVD.Keywords
This publication has 1 reference indexed in Scilit: